TR200101754T2 - Farnezil protein transferaz inhibitörleri - Google Patents

Farnezil protein transferaz inhibitörleri

Info

Publication number
TR200101754T2
TR200101754T2 TR2001/01754T TR200101754T TR200101754T2 TR 200101754 T2 TR200101754 T2 TR 200101754T2 TR 2001/01754 T TR2001/01754 T TR 2001/01754T TR 200101754 T TR200101754 T TR 200101754T TR 200101754 T2 TR200101754 T2 TR 200101754T2
Authority
TR
Turkey
Prior art keywords
protein transferase
farnesyl protein
transferase inhibitors
denotes
disclosed
Prior art date
Application number
TR2001/01754T
Other languages
English (en)
Turkish (tr)
Inventor
Guzi Timothy
F. Rane Dinanath
K. Mallams Alan
B. Cooper Alan
J. Doll Ronald
M. Girijavallabhan Viyyoor
G. Taveras Arthur
Strickland Corey
M. Kelly Joseph
Chao Jianping
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of TR200101754T2 publication Critical patent/TR200101754T2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR2001/01754T 1998-12-18 1999-12-16 Farnezil protein transferaz inhibitörleri TR200101754T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21656098A 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
TR200101754T2 true TR200101754T2 (tr) 2002-05-21

Family

ID=22807539

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01754T TR200101754T2 (tr) 1998-12-18 1999-12-16 Farnezil protein transferaz inhibitörleri

Country Status (23)

Country Link
EP (1) EP1140904B1 (enExample)
JP (1) JP2002533335A (enExample)
KR (1) KR20010081115A (enExample)
CN (1) CN1285588C (enExample)
AR (1) AR021716A1 (enExample)
AT (1) ATE293622T1 (enExample)
AU (1) AU2347900A (enExample)
BR (1) BR9916328A (enExample)
CA (1) CA2354774C (enExample)
CO (1) CO5160344A1 (enExample)
CZ (1) CZ20011900A3 (enExample)
DE (1) DE69924876T2 (enExample)
ES (1) ES2237963T3 (enExample)
HU (1) HUP0203054A3 (enExample)
ID (1) ID29065A (enExample)
IL (1) IL143409A0 (enExample)
NO (1) NO20012960L (enExample)
PE (1) PE20001516A1 (enExample)
PL (1) PL348294A1 (enExample)
SK (1) SK7582001A3 (enExample)
TR (1) TR200101754T2 (enExample)
WO (1) WO2000037458A1 (enExample)
ZA (1) ZA200104236B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034567A1 (en) * 1999-11-10 2001-05-17 Aventis Pharma Deutschland Gmbh N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
US7361663B2 (en) 1999-11-10 2008-04-22 Aventis Pharmaceuticals Inc. N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6809093B2 (en) 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
EP1632483B1 (en) 2001-02-16 2008-10-29 Aventis Pharmaceuticals Inc. Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
WO2002080895A2 (en) * 2001-04-06 2002-10-17 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
ATE409065T1 (de) * 2002-12-17 2008-10-15 Schering Corp Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
WO2006065828A2 (en) 2004-12-13 2006-06-22 Schering Corporation Novel farnesyl protein transferase inhibitors and their use to treat cancer
MX2007007078A (es) 2004-12-14 2007-09-04 Schering Corp Inhibidores de farnesil-transferasa de proteina y metodos para tratar las enfermedades proliferativas.
CN101400656A (zh) * 2006-01-19 2009-04-01 先灵公司 作为法呢基蛋白转移酶抑制剂的哌嗪衍生物
CN102123999B (zh) * 2008-05-22 2014-06-18 默沙东公司 制备食欲素受体拮抗剂的方法
HU231150B1 (hu) 2017-03-13 2021-03-29 Richter Gedeon Nyrt Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására
AU2020286381C1 (en) 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
CN116075514A (zh) 2020-08-05 2023-05-05 吉瑞工厂 药理学活性的杂环取代的吡唑并[1,5-a]嘧啶衍生物
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种(R)-1-Boc-3-羟甲基哌嗪的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
GB9420172D0 (en) * 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
PE104798A1 (es) * 1997-06-17 1999-11-06 Pharmacopeia Inc Compuestos utiles para la inhibicion de la enzima farnesilo transferasa

Also Published As

Publication number Publication date
CN1285588C (zh) 2006-11-22
SK7582001A3 (en) 2002-03-05
AU2347900A (en) 2000-07-12
WO2000037458A1 (en) 2000-06-29
NO20012960D0 (no) 2001-06-15
ZA200104236B (en) 2002-08-23
PE20001516A1 (es) 2001-01-06
BR9916328A (pt) 2001-10-02
DE69924876D1 (de) 2005-05-25
DE69924876T2 (de) 2006-03-02
CZ20011900A3 (cs) 2002-02-13
CN1352642A (zh) 2002-06-05
HUP0203054A2 (hu) 2003-01-28
KR20010081115A (ko) 2001-08-27
ES2237963T3 (es) 2005-08-01
AR021716A1 (es) 2002-07-31
CA2354774A1 (en) 2000-06-29
JP2002533335A (ja) 2002-10-08
HK1036279A1 (en) 2001-12-28
PL348294A1 (en) 2002-05-20
ID29065A (id) 2001-07-26
HUP0203054A3 (en) 2004-01-28
NO20012960L (no) 2001-08-15
IL143409A0 (en) 2002-04-21
EP1140904A1 (en) 2001-10-10
ATE293622T1 (de) 2005-05-15
CO5160344A1 (es) 2002-05-30
EP1140904B1 (en) 2005-04-20
CA2354774C (en) 2009-05-26

Similar Documents

Publication Publication Date Title
TR200101754T2 (tr) Farnezil protein transferaz inhibitörleri
GB9919776D0 (en) Compoujnds
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
DK0927161T3 (da) Substitueret cyklisk amin-metalloproteaseinhibitorer
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
ES2196186T3 (es) Inhibidores de protein-isoprenil-transferasas.
ATE377004T1 (de) Proteinkinaseinhibitoren
ATE457025T1 (de) Kinaseinhibitoren
PT1076663E (pt) Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase
DE69812634D1 (de) Metalloproteinase-inhibitoren
BR9812922A (pt) Isoquinolinas como inibidores de uroquinase
NZ512292A (en) Sulfonamide hydroxamates that inhibit procollagen C- proteinase
DK1706414T3 (da) Fremgangsmåde til fluorcytidinderivater
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса
TR200003859T2 (tr) Amidino ve guanidino azetidinon triptaz önleyicileri
TR199800243T1 (xx) Prolil endopeptidaz inhibit�rleri.
NO971142L (no) Bis-(2-halogenetyl)aminofenylsubstituerte distamycinderivater som antitumor- og antivirale midler
ATE239741T1 (de) Derivate der phosphonsäure zur inhibierung von carboxypeptidase b
TR200101755T2 (tr) Trisiklik farnezil protein transferaz inhibitörleri.
NO981340L (no) Stabiliserte fosfolipidsammensetninger
BR9912374A (pt) Isoquinolinas como inibidores de urocinase
BR0311749A (pt) Processo para produzir um composto, e, composto
NO991097L (no) Nye fremgangsmÕter
BR0009856A (pt) Sìntese de 3-amino-3-aril propanoatos